Capecitabine showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (moderate certainty).
It is very uncertain whether capecitabine changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
It is very uncertain whether capecitabine changes time to progression compared with 5‐FU‐containing regimens (very low certainty).
It is very uncertain whether capecitabine changes progression‐free survival compared with 5‐FU‐containing regimens (very low certainty).
It is very uncertain whether capecitabine changes treatment‐related death compared with 5‐FU‐containing regimens (very low certainty).
Capecitabine showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (low certainty).
Capecitabine‐containing regimens showed no clear difference in overall survival (OS)median compared with chemotherapy regimens without capecitabine (high certainty).
Capecitabine‐containing regimens showed no clear difference in pCR: hormone receptor‐positive compared with non‐capecitabine‐containing regimens (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in pCR: hormone receptor‐negative compared with non‐capecitabine‐containing regimens (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in disease‐free survivalmedian compared with non‐capecitabine‐containing regimens (high certainty).
Capecitabine‐containing regimens showed no clear difference in overall survivalmedian compared with non‐capecitabine‐containing regimens (high certainty).
Capecitabine‐containing regimens showed no clear difference in febrile neutropenia compared with non‐capecitabine‐containing regimens (moderate certainty).
Capecitabine‐containing regimens probably leads to higher diarrhoea compared with non‐capecitabine‐containing regimens (moderate certainty).
Capecitabine‐containing regimens probably leads to higher hand‐foot syndrome compared with non‐capecitabine‐containing regimens (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in disease‐free survival (DFS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in DFS: hormone receptor‐positivemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens probably leads to lower DFS: hormone receptor‐negativemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (high certainty).
Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).